Pfizer Oncology ASCO 2008 Media Briefing to Discuss Study Results in Broad Range of Cancers

Business Wire, May 30, 2008

WHAT:   Pfizer Oncology will host a journalist briefing at the American
        Society of Clinical Oncology (ASCO) Annual Meeting on Sunday,
        June 1, 2008, highlighting key data presentations from a variety
        of compounds in several difficult-to-treat tumor types,
        including renal cell carcinoma and non-small cell lung cancer.
        Leading oncology physicians and researchers will present study
        results and offer their professional perspective.

WHO:    Robert Figlin, M.D., F.A.C.P., City of Hope
        Abstract #5024: "Overall survival with sunitinib versus
        interferon (IFN)-alfa as first-line treatment of metastatic
        renal cell carcinoma (mRCC)"

        Antonio Gualberto, M.D., Ph.D., Pfizer Global Research and
        Development
        Abstract #10501: "Safety, pharmacokinetics and preliminary
        activity of the anti-IGF-1R antibody CP-751,871 in
        sarcoma patients"

        Daniel Karp, M.D., M.D. Anderson Cancer Center
        Abstract #8000: "Characterization of NSCLC patients responding
        to anti-IGF-1R therapy"

        Pasi A. Janne, M.D., Ph.D., Dana-Farber Cancer Institute
        Abstract #8027, Poster #8: "Preliminary activity and safety
        results from a phase I clinical trial of PF-00299804, an
        irreversible pan-HER inhibitor, in patients (pts) with NSCLC"

        John H. Sampson, M.D., Ph.D., Duke University Medical Center
        Abstract #2061: "Effect of EGFRvIII-targeted vaccine (CDX-110)
        on immune response and TTP when given with simultaneous standard
        and continuous temozolomide in patients with GBM"

WHEN:   Sunday, June 1, 2008 at 6:00 PM (CT)

WHERE:  Westin River North - Grand Ballroom A&B
        320 N. Dearborn Avenue
        Chicago, IL 60610
        (312) 744-1900